|
 Hello Immunization Partners,
Please share the following information with staff and colleagues.
The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) are recommending a pause in the use of IXCHIQ (Chikungunya Vaccine, Live) in persons 60 years of age and older while they investigate post marketing reports of serious adverse events, including neurologic and cardiac events, in individuals who have received the vaccine.
The FDA and CDC recently investigated five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ among older people. They are also aware of additional serious adverse events in older people in other countries. Due to this, FDA and CDC advise that persons 60 years and older should not receive the live-attenuated vaccine IXCHIQ until these additional reports are further investigated. FDA and CDC will update the public once they complete their evaluation of this safety issue.
Thank you for all you do to protect Michiganders from vaccine preventable diseases.
Oakland County Health & Human Services, Immunization Action Plan
|
|
|
|
